Johnson and Johnson successfully applied for a patent extension on bedaquiline; however, in a big win for LMI countries, the company has decided not to enforce its patent, allowing generic producers to manufacture the drug. Additionally, J&J has reduced the price of bedaquiline for South Africa by around 40%, making it more affordable for the country. J&J’s reversal of its past decisions regarding bedaquiline was prompted by an investigation of the company’s pricing policies led by the South African government. Learn more here.
top of page
Recent Posts
See AllThis week, the WHO recommended four new treatments for patients with MDR-TB. Three of the regimens were from the End TB trial, and one...
90
The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to...
260
Members of the resist TB team recently published an open access letter to the editor regarding the effectiveness of consilia. Please find...
220
bottom of page
Commentaires